ESMO 2026 Impact Survey: What Oncologists Expect to Change in Cancer Care
Our survey of 88 oncologists across seven countries examines the ESMO 2026 data they consider most important and its potential influence on treatment decisions.
Among surveyed oncologists who treat lung cancer, 79% said the data presented at ESMO 2026 were somewhat or extremely likely to change their treatment approach over the next three to five years. Among those treating breast cancer, that figure was 75%.
For biopharma teams, these expectations raise questions about evidence generation, clinical differentiation and how to communicate emerging data.
The Syneos Health ESMO 2026 Impact Survey captures perspectives from 88 practicing oncologists who attended the European Society for Medical Oncology Congress in person. Conducted in October–November 2026, the survey explores:
- Clinical data with anticipated treatment impact: Which presentations respondents considered most important and where they expect changes in treatment approaches across cancer types.
- Interest in emerging oncology therapies: How oncologists rated multi-targeted antibodies, antibody-drug conjugates, next-generation small molecules and cell-based therapies.
- Molecular targets shaping expectations: Which targets generated the greatest excitement about their potential to influence future standards of care.
- Perceptions of oncology companies: Which established and emerging manufacturers respondents expect to influence cancer treatment.
- AI applications in routine practice: Which approaches oncologists believe could influence care within the next 12–24 months, including precision oncology implementation, multimodal analysis and treatment selection.
Read the full findings to inform discussions about oncology development priorities, medical education and competitive positioning.
Related Content
Looking for exclusive insight?
